Greenberg, J A
Manson, J E
Tinker, L
Neuhouser, M L
Garcia, L
Vitolins, M Z
Phillips, L S
Article History
Received: 10 October 2016
Revised: 20 February 2017
Accepted: 25 February 2017
First Online: 12 April 2017
Competing interests
: JM and colleagues at Brigham and Women’s Hospital, Harvard Medical School are recipients of funding from Mars Symbioscience for an investigator-initiated randomized trial of cocoa flavanols and cardiovascular disease. JG is the recipient of funding from the City University of New York Research Award Program to conduct a pilot randomized trial of cocoa compounds and appetite. LP has served on Scientific Advisory Boards for Boehringer Ingelheim and Janssen within the past several years, and has or had research support from Merck, Amylin, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, and the Cystic Fibrosis Foundation. In the past, he was a speaker for Novartis and Merck. He is also a co-founder of a company, Diasyst LLC, which aims to develop and commercialize diabetes management software programs. These activities involve diabetes, but have nothing to do with this manuscript. The remaining authors declare no conflict of interest.